HomeFinTechRecce Pharmaceuticals: Expands and accelerates clinical programs

Recce Pharmaceuticals: Expands and accelerates clinical programs

Date:

Flex Expands Consumer Reach Through Strategic Maza Acquisition

Unlocking New Opportunities in Consumer Markets with Innovative Solutions Highlights:...

Mongolian Fintech LendMN Secures $20 Million to Enhance Financial Inclusion

Revolutionizing Access to Financial Services in Mongolia Highlights: LendMN raises...

Recce Pharmaceuticals Expands and accelerates clinical programs

  • Recce Pharmaceuticals (RCE) updates its clinical timeline, with several data read-outs expected over this year and next year
  • The company expects to dose its first subject under a phase 1b/2a multi-dose and early-stage sepsis study later this year
  • Meanwhile, new data from antoher phase one clinical trial of R327 supports findings from pre-clinical in-vivo kidney and UTI bacterial infection studies
  • Furthermore, Recce has designed a new phase two study for R327 for treating diabetic foot ulcer infections, with the first patient to be dosed before the end of the year
  • Shares in ReccePharmaceuticals are trading 6.15 per cent higher at 69 cents each at 2:59 pm AEST
Exit mobile version